Cargando…

Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study

OBJECTIVES: To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. METHODS: We retrospectively analyzed the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haitao, Li, Yahua, Wang, Yang, Yan, Lei, Zhou, Pengli, Han, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981896/
https://www.ncbi.nlm.nih.gov/pubmed/33743767
http://dx.doi.org/10.1186/s13019-021-01418-w
_version_ 1783667607258267648
author Liu, Haitao
Li, Yahua
Wang, Yang
Yan, Lei
Zhou, Pengli
Han, Xinwei
author_facet Liu, Haitao
Li, Yahua
Wang, Yang
Yan, Lei
Zhou, Pengli
Han, Xinwei
author_sort Liu, Haitao
collection PubMed
description OBJECTIVES: To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. METHODS: We retrospectively analyzed the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors and summarized the patient’s sex, age, tumor type, endovascular treatment plan, complications and postoperative follow-up. RESULTS: All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty-seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents and 4 covered stents. The technical success rate was 100%, and there were no serious surgery-related complications. The remission rate of clinical symptoms was 53.1% (17/32) at 24 h and 84.4% (27/32) at 48 h. After 48 h, the symptoms of the remaining patients were slowly relieved, and the symptom relief rate was 100% at 7 days. The follow-up period was 1.5–24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had restenosis and 1 patient had secondary thrombosis in the stent. Their symptoms were relieved after the second treatment. CONCLUSION: For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low.
format Online
Article
Text
id pubmed-7981896
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79818962021-03-22 Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study Liu, Haitao Li, Yahua Wang, Yang Yan, Lei Zhou, Pengli Han, Xinwei J Cardiothorac Surg Research Article OBJECTIVES: To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. METHODS: We retrospectively analyzed the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors and summarized the patient’s sex, age, tumor type, endovascular treatment plan, complications and postoperative follow-up. RESULTS: All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty-seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents and 4 covered stents. The technical success rate was 100%, and there were no serious surgery-related complications. The remission rate of clinical symptoms was 53.1% (17/32) at 24 h and 84.4% (27/32) at 48 h. After 48 h, the symptoms of the remaining patients were slowly relieved, and the symptom relief rate was 100% at 7 days. The follow-up period was 1.5–24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had restenosis and 1 patient had secondary thrombosis in the stent. Their symptoms were relieved after the second treatment. CONCLUSION: For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low. BioMed Central 2021-03-20 /pmc/articles/PMC7981896/ /pubmed/33743767 http://dx.doi.org/10.1186/s13019-021-01418-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Liu, Haitao
Li, Yahua
Wang, Yang
Yan, Lei
Zhou, Pengli
Han, Xinwei
Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title_full Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title_fullStr Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title_full_unstemmed Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title_short Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
title_sort percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981896/
https://www.ncbi.nlm.nih.gov/pubmed/33743767
http://dx.doi.org/10.1186/s13019-021-01418-w
work_keys_str_mv AT liuhaitao percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy
AT liyahua percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy
AT wangyang percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy
AT yanlei percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy
AT zhoupengli percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy
AT hanxinwei percutaneoustransluminalstentingforsuperiorvenacavasyndromecausedbymalignanttumorsasinglecenterretrospectivestudy